Haemonetics Stock

Haemonetics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Haemonetics (HAE) as of Sep 10, 2026 is 241.40 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 270.08 M USD — a change of -10.62% (lower).

EBITDA

241.40 MUSD

YoY

-10.62%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Haemonetics is 2026 241.40 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Haemonetics was 2025 270.08 M USD. It decreases by -10.62% lower compared to the previous year.

The Haemonetics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
83.55 M USD
Jan 1, 2020
119.55 M USD
Jan 1, 2021
122.55 M USD
Jan 1, 2022
128.15 M USD
Jan 1, 2023
188.63 M USD
Jan 1, 2024
196.91 M USD
Jan 1, 2025
270.08 M USD
Jan 1, 2026
241.40 M USD
The Haemonetics EBITDA history
YEAREBITDAYoY
241.40 MUSD-10.62%
270.08 MUSD+37.16%
196.91 MUSD+4.39%
188.63 MUSD+47.20%
128.15 MUSD+4.57%
122.55 MUSD+2.51%
119.55 MUSD+43.10%
83.55 MUSD+37.68%
60.68 MUSD+54.75%
39.21 MUSD-189.24%
-43.94 MUSD-162.12%
70.74 MUSD+49.47%
47.33 MUSD
Access this data via the Eulerpool API

Haemonetics Stock analysis

What does Haemonetics do? Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Haemonetics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Haemonetics is 241.40 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Haemonetics changed from 270.08 M USD to 241.40 M USD, representing a -10.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Haemonetics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Haemonetics historically and in real time.

Access this data via the Eulerpool API

Income Statement — Haemonetics

All Key Metrics — Haemonetics